Briefings covering the 30-day period through 2026-07-19 recorded no material discrete corporate events, new regulatory disclosures, or new corporate announcements for AbbVie Inc. Successive briefs dated 2026-06-09 through 2026-07-19 each noted the absence of new filings beyond routine continuations. No new FDA actions, pipeline updates, or material litigation disclosures were reported within the covered period [Brief - 2026-07-19] [Brief - 2026-07-11] [Brief - 2026-07-03].
As of the quarter ending 2026-03-31, AbbVie reported trailing twelve-month revenue of $62.82 billion, reflecting year-over-year growth of 12.43%. Net income for the same period stood at $3.64 billion, with a net margin of 5.79% and an operating margin of 24.41%. Gross margin was recorded at 67.37%. Earnings per share declined 45.83% year-over-year. The company held $9.39 billion in cash against total debt of $64.50 billion. The reported P/E ratio was 127.76 [SEC 10-Q - ABBV - 2026-03-31].
Institutional ownership data reflects material position changes across several notable filers. Millennium Management added 61% to its ABBV position, while Bridgewater Associates increased its holding by 114%. Conversely, Citadel reduced its position by 11% and AQR Capital Management reduced its position by 23%. These divergent adjustments among large systematic and multi-strategy managers constitute the primary trigger for this report [SEC 13F - Millennium - Q2 2026] [SEC 13F - Bridgewater - Q2 2026] [SEC 13F - Citadel - Q2 2026] [SEC 13F - AQR Capital - Q2 2026].
The prevailing macro environment shows the 10-year US Treasury yield at 4.71% and the 2-year yield at 4.37%, producing a normal yield curve with a 34-basis-point spread [FRED DGS10] [FRED DGS2]. AbbVie's total debt of $64.50 billion relative to its cash position of $9.39 billion places its net debt servicing in the context of a sustained elevated rate environment, where refinancing conditions remain materially different from the low-rate period in which much of that debt was accumulated.